Objectives: To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods: People living with HIV from the prospective ANRS‐CO3‐AquiVIH‐NA cohort, who switched from effective antiretroviral treatment (ART) to a BIC‐ or DTG‐based regimen between 2018 and 2021, were eligible for analysis. Results: A total of 2275 people living with HIV were included (52% receiving B/F/TAF, 8% DTG/3TC/ABC, 18% DTG/RPV, 22% DTG/3TC) with a median age of 53–56 years and a comorbidity prevalence of 71%–75% across treatment groups (chronic kidney disease (CKD) 15%–25%, diabetes mellitus 15%–19%, hypertension 57%–64%). Viral suppression rates at month 18 (LOCF, last observation carried forward) using a missing‐equals‐excluded (M = E) approach were 97% on B/F/TAF, 95% on DTG/3TC/ABC, 97% on DTG/RPV and 96% on DTG/3TC. Discontinuation rates were 16.5% for B/F/TAF, 37.5% for DTG/3TC/ABC, 16.7% for DTG/RPV and 17.3% for DTG/3TC, driven by adverse events in 5.6%, 12.5%, 5.6% and 6.1%, respectively. Comorbidity incidence rates/1000 person years in those free of the respective disease were 39 for hypertension, 22 for diabetes mellitus, 13 for cardiovascular events and 5 for CKD. Conclusions: In this real‐world cohort, treatment persistence 18 months after therapy switch was similar for B/F/TAF, DTG/RPV and DTG/3TC, but significantly lower for DTG/3TC/ABC. All regimens maintained high levels of viral suppression. Furthermore, the cohort illustrates the disease burden experienced by middle‐aged and elderly people living with HIV and highlights the importance of adapting ART to the specific needs of this population.